

Full blots corresponding to each Figure

Figure 4. (c) CHD3^{NEMO} disrupts vFLIP/NEMO interaction in live cells.







Figure 6 (d) Mice treated with **CHD3^{NEMO}** for 24hrs have attenuated NF- κ B signaling in tumor cells.




Supplementary Figure 5. CHD3^{NEMO} inhibits NF- κ B signaling in BC1 PEL cell line.



Supplementary Figure 6. CHD3^{NEMO} pretreatment does not block TNF α stimulation and NF- κ B signaling in HeLa cells.




Supplementary Figure 7. CHD3^{NEMO} treatment downregulates vFLIP target expression in BC-1 PEL cells




*24hr Included in paper

Supplementary Figure 8. CHD3^{NEMO} treatment decreases vFLIP association with NEMO in BC-1 PEL cells



Supplementary Figure 9. Effect of CHD3^{NEMO} on NEMO levels in Namalwa cells expressing vFLIP target



Supplementary Figure 10. (a) and (b) vFLIP NF- κ B dead mutant has a reduced half-life compared to WT vFLIP and MG-132 stabilizes its protein expression. (c)) CHD3^{NEMO} treatment disrupts vFLIP/NEMO interaction and targets them for proteasomal degradation

